Traws Pharma, Inc. Balance Sheet
TRAW|12 years of annual SEC 10-K data (FY2013-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$11M
FY2024
Cash
N/A
Cash and equivalents
Total Debt
N/A
FY2024
Shareholder Equity
-$32M
FY2024
Traws Pharma, Inc. had $11M in total assets with negative shareholders' equity of $32M as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | - | - | - | - | - | - | - | $19.8M | $43.6M | $60.0M | $2.7M |
| Current Assets | $8.0M | $22.7M | $39.3M | $55.4M | $19.8M | $23.5M | $17.8M | $4.9M | $23.1M | $23.2M | $46.9M | $104.4M |
| PP&E (Net) | $7.0K | $22.0K | $24.0K | $38.0K | $52.0K | $50.0K | $9.0K | $64.0K | $152.0K | $248.0K | $420.0K | $626.0K |
| Total Assets | $10.6M | $22.7M | $39.4M | $55.5M | $20.0M | $23.7M | $17.9M | $5.0M | $23.2M | $23.4M | $47.3M | $105.2M |
| Current Liabilities | $11.1M | $9.2M | $8.0M | $6.1M | $10.0M | $8.3M | $8.4M | $10.0M | $10.2M | $7.6M | $10.3M | $10.3M |
| Shareholders' Equity | -$31.6M | $28.3M | $46.1M | $6.2M | $11.6M | $5.4M | $5.4M | -$11.7M | $4.3M | $10.0M | $22.7M | $80.4M |